Table 2 |
|||||||
|
Immunomodulatory Non-Glucan Extracts: Oral Animal Studies |
|||||||
|
Extract |
Source |
Animal |
Oral dose/day |
Duration |
Treatment |
Significant effects |
Reference |
|
|
|||||||
|
Fucoidans |
Cladosiphon okamuranus Tokida |
8-week ♀ BALB/c mice, 10/group |
0.05% w/w of diet |
56 days |
DSS-induced UC |
↓ disease activity index and myeloperoxidase activity; ↓ # of B220-positive colonic B cells; ↓ colonic MLN IFN-γ and IL-6 and ↑ IL-10 and TGF-β; ↓ colonic IgG; ↓ colonic epithelial cell IL-6, TNF-α, and TLR4 mRNA expression |
[49] |
|
|
|||||||
|
Undaria pinnatifida |
5-week ♀ BALB/c mice (10-12/group) |
5 mg, days 1-14 or 7-14 |
2 weeks |
Injected HSV into cornea day 7 |
↓ facial herpetic lesions; ↑ survival, particularly in pre-treated animals |
[45] |
|
|
|
|||||||
|
10 mg |
1 week |
Administered 5-fluorouracil |
↑ plasma NK cell activity |
||||
|
|
|||||||
|
Injected SC HSV |
↑ cytotoxic splenic T lymphocyte activity |
||||||
|
|
|||||||
|
0.1 or 0.5 mg |
3 weeks |
Injected IP HSV |
Both doses ↑ serum neutralizing Ab titers, weeks 2 and 3 |
||||
|
|
|||||||
|
6-week ♂ ddY mice (5/group) |
50, 100, 200 400 or 500 mg/kg days 1-28 |
3 weeks |
Injected with Ehrlich carcinoma in back day 14 |
200-500 mg/kg ↓ tumor growth |
[116] |
||
|
|
|||||||
|
6-week ♂ BALB/c mice (8/group) |
40 mg/kg alternating days 7-19 |
19 days |
Injected IP Meth A fibrosarcoma day 1 |
↓ tumor growth |
|||
|
|
|||||||
|
Furanose (COLD-FX®) |
Panax quinquefolium |
Weanling ♂ SD rats (10/group) |
450 or 900 mg/kg in food |
1 week |
Healthy animals |
Both doses ↑ spleen Il-2 and IFN-γ production following ConA or LPS stimulation; ↓ proportion of total MLN and Peyer's patch CD3+ cells & activated T cells; high dose ↑ spleen cell IL-1β production following 48 h ConA stimulation. |
[33] |
|
|
|||||||
|
Galacto-mannan (partially hydrolyzed guar gum) |
Cyamopsis tetragonolobus |
10-week ♀ BALB/c mice, 11-15/group |
5% of diet |
3 weeks |
DSS-induced UC at beginning of week 3 |
↓ disease activity index scores, ↓ colonic mucosal myeloperoxidase activity & lipid peroxidation; ↓ colonic TNF-α protein levels & mRNA expression up regulated by DSS exposure |
[50] |
|
|
|
||||||
|
Galacto-mannans (guar gum) |
8-month- SD rats, 5/group |
5% of diet |
3 weeks |
Older animals |
↓ serum IgG; ↑ MLN lymphocyte IgA, IgM and IgG production |
[36] |
|
|
|
|||||||
|
Glucomannan (KS-2) |
Lentinula edodes |
DD1 mice (10-20/group) |
140 mg/kg days 2-13 |
50 days |
Injected IP Ehrlich ascites tumor cells day 1 |
↑ survival |
[84] |
|
|
|||||||
|
0.1, 1, 10, or 100 mg/kg dose days 2-13 |
100 days |
Injected Sarcoma-180 tumor cells day 1 |
1, 10, and 100 mg/kg doses ↑ survival |
||||
|
|
|||||||
|
Heteroglycan (ATOM) |
A. subrufescens |
Mice (10/group): 1) 5-week ♂ Swiss/NIH; 6 week- ♀ DS mice; 3) 8-week ♀ BALB/c nude; 4) 5-week C3H/HcN |
100 or 300 mg/kg days 2-11 |
8 weeks |
Implanted SC 1) Sarcoma-180, 2) Shionogi carcinoma 42, 3) Meth A fibrosarcoma, or 4) Ehrlich ascites carcinoma cells |
Both doses ↓ Sarcoma-180 tumor size at 4 weeks & ↑ survival; 300 mg/kg ↑ peritoneal macrophage and C3-positive cells; 300 mg/kg ↓ Shionogi and Meth A tumor sizes at 4 weeks. Both doses ↑ survival of Ehrlich ascites mice |
[93] |
|
|
|||||||
|
Heteroglycan (LBP3p) |
Lycium barbarum |
♂ Kunming mice (10/group) |
5, 10 or 20 mg/kg |
10 days |
Injected SC Sarcoma-180 cells |
5 & 10 mg/kg ↑ thymus index; all doses ↓ weight, ↓ lipid peroxidation in serum, liver and spleen & ↑ spleen lymphocyte proliferation, cytotoxic T cell activity, IL-2 mRNA |
[91] |
|
|
|||||||
|
Heteroglycan (PNPS-1) |
Pholiota nameko |
SD rats (5/group) |
100, 200 or 400 mg/kg days 1-8 |
8 days |
Implanted SC cotton pellets in scapular region day 1 |
↓ granuloma growth positively correlated with dose: 11%, 18% and 44%, respectively |
[55] |
|
|
|||||||
|
Heteroglycan (PG101) |
Lentinus lepideus |
8-10-week ♀ BALB/c mice (3/group) |
10 mg |
24 days |
6 Gy gamma irradiation |
↑ colony forming cells, granulocyte CFUs/Mø, erythroid burst-forming units, and myeloid progenitor cells in bone marrow; induced proliferation of granulocyte progenitor cells in bone marrow; ↑ serum levels of GM-CSF, IL-6, IL-1β |
[92] |
|
|
|||||||
|
Mixed poly-saccharides (Ambrotose® or Advanced Ambrotose® powders) |
Aloe barbadensis, Larix spp, and other plant poly-saccharides |
♂ SD rats (10/group) |
37.7 or 377 mg/kg Ambrotose® powder or 57.4 or 574 mg/kg Advanced Ambrotose® powder |
2 weeks |
5% DSS in drinking water beginning day 6 |
574 mg/kg Advanced Ambrotose powder ↓ DAI scores; 377 mg/kg Ambrotose complex & both doses Advanced Ambrotose powder ↑ colon length and ↓ blood monocyte count |
[52] |
|
|
|||||||
|
Pectin |
Pyrus pyrifolia |
6-8-week ♂ BALB/c mice (11/group) |
100 μg days 1-7 |
22 days |
Injected IP OVA day 7, provoked with OVA aerosol day 21 |
bronchial fluid:↓ IFN-γ & ↑ IL-5; splenic cells: ↑ IFN-γ, ↓ IL-5; normalized pulmonary histopathological changes; ↓ serum IgE |
[54] |
|
|
|||||||
|
Pectins (bupleurum 2IIc) |
Bupleurum falcatum |
6-8-week ♀ specific-pathogen-free C3H/HeJ mice |
250 mg/kg |
1 week |
Healthy animals |
↑ spleen cell proliferation |
[35] |
|
|
|||||||
|
Pectins (highly methoxylated) |
Malus spp. |
8-month- SD rats (5/group) |
5% of diet vs. cellulose control |
3 weeks |
Older animals |
↑ MLN lymphocyte IgA & IgG |
[36] |
|
|
|||||||
|
Pectins |
Citrus spp. |
5-week ♀ F344 rats (30/group) |
15% of diet |
34 weeks |
Injected SC AOM once a week, weeks 4-14 |
↓ colon tumor incidence |
[86] |
|
|
|||||||
|
Malus spp. |
5-week ♀ BALB/c mice (6/group) |
5% of diet |
2 weeks |
Healthy animals |
↑ fecal IgA and MLN CD4+/CD8+ T lymphocyte ratio & IL-2 & IFN-γ secretion by ConA-stimulated MLN lymphocytes |
[51] |
|
|
|
|||||||
|
5-week ♀ BALB/c mice (6/group) |
5% of diet days 5-19 vs. cellulose control |
19 days |
DSS-induced UC days 1-5 |
Significantly increased MLN lymphocytes IgA, and significantly decreased IgE; significantly decreased ConA-stimulated IL-4 and IL-10 |
|||
|
|
|||||||
|
4-week ♂ Donryu rats (20-21/group) |
20% of diet |
32 weeks |
Injected SC AOM once a week, weeks 2-12 |
↓ colon tumor incidence |
[85] |
||
|
|
|||||||
|
4-week ♂ Donryu rats (19-20/group) |
10 or 20% of diet |
32 weeks |
Injected SC AOM once a week, weeks 2-12 |
Both doses ↓ colon tumor incidence; 20% ↓ tumor occupied area & ↓ portal blood and distal colon PGE2 |
[90] |
||
|
|
|||||||
|
Pectins (modified) |
Citrus spp. |
2-4-month BALB/c mice (9-10/group) |
0.8 or 1.6 mg/ml drinking water, days 8-20 |
20 days |
Injected SC with 2 × 2 mm section of human colon-25 tumor on day 1 |
Both doses ↓ tumor size |
[87] |
|
|
|||||||
|
NCR nu/nu mice (10/group) |
1% (w/v) drinking water |
16 weeks |
Orthotopically injected human breast carcinoma cells (MDA-MB-435) into mammary fat pad on day 7 |
↓ tumor growth rate & volume at 7 weeks, lung metastases at 15 weeks, # of blood vessels/tumor at 33 days post-injection |
[89] |
||
|
|
|||||||
|
NCR nu/nu mice (10/group) |
1% (w/v) drinking water |
7 weeks |
Injected human colon carcinoma cells (LSLiL6) into cecum on day 7 |
↓ tumor weights and metastases to the lymph nodes and liver |
|||
|
|
|||||||
|
SD rats (7-8/group) |
0.01%, 0.1% or 1.0% wt/vol of drinking water, days 4-30 |
1 month |
Injected SC MAT-LyLu rat prostate cancer cells |
0.1% and 1.0% ↓ lung metastases; 1.0% ↓ lymph node disease incidence |
[88] |
||
|
|
|||||||
|
Ramberg et al. Nutrition Journal 2010 9:54 doi:10.1186/1475-2891-9-54 |
|||||||